Nitesh N. Paryani's research while affiliated with Mayo Foundation for Medical Education and Research and other places

... 11 Second, the Mayo Clinic study which included 282 consecutive patients (99 adenocarcinoma) with early-stage NSCLC, showed that Pre-SBRT FDG-PET-CT SUV max value (continuous) was associated with the risk of any failure (p = 0.02) but not with local failure only (p = 0.69). 19 The results of these two studies are in accordance with our study findings and demonstrate the prognostic importance of pre-SBRT FDG-PET-CT. ...

... The liver is the most common metastatic organ in patients J Gastrointest Oncol 2022;13 (3) Divorced/separated 30 [13] 83 [12] 30 [13] 29 [13] Single/unmarried 44 [19] 124 [18] 41 [18] 44 [20] Widowed/other 47 [20] 69 [10] 40 [18] 44 [20] Year of diagnosis, n [%] 0.053 0.264 2010 50 [21] 102 [15] 49 [22] 46 [21] 2011 28 [12] 116 [17] 26 [12] 42 [19] 2012 39 [17] 113 [16] 37 [17] 31 [14] 2013 42 [18] 92 [13] 40 [18] 29 [13] 2014 35 [15] 122 [18] 33 [15] 32 [14] 2015 42 [18] 140 [20] 39 [17] 44 [20] Tumor T3 33 [14] 138 [20] 33 [15] 36 [16] T4 34 [14] 103 [15] 30 [13] 35 [16] Tx Other 39 [17] 106 [15] 36 [16] 41 [18] *, statistically significant. Percentages were calculated after excluding missing cases from the denominator. ...

... Smaller studies previously evaluated the expression of p53, Bcl-2 and Ki-67 [27][28][29]. Lee et al. developed a scoring system that provides an estimation risk of biochemical failure after salvage radiotherapy, based on PSA, pathological tumor stage, Gleason score and surgical margin status with a c-index of 0.66 [30]. ...

... Of these, between 15% and 25% will experience a significant rise in their serum prostate specific antigen level following surgery, indicating a biochemical recurrence (BCR) of their disease [1]. The only potentially curative treatment option available to men who have experienced BCR of prostate cancer after RP is salvage radiation therapy (SRT); however, the reported success of SRT have ranged from 10% to 65% [2][3][4][5][6][7][8][9][10]. As such, the ability to accurately identify which men have the highest likelihood of responding to SRT represents a key clinical issue for the field. ...

... Dosimetric characteristics of this source design have been evaluated using the MC simulation technique following the TG-43 recommendations [7,8,9,10,11,12,13,14,15]. Although dosimetric characteristics of these sources have been evaluated using the TG-43 formalism, their clinical applications have not been fully explored, partic-ularly in the U.S. For example, the AccuBoost technique has been introduced (Advanced Radiation Therapy, LLC, Tyngsboro, MA, USA) [19,20,21] for boost or accelerated partial breast irradiation (APBI) treatment modalities [22,23] using non-invasive image-guided breast brachytherapy (NIBB) [24,25] in contrast to other interstitial techniques [26,27,28,29]. The clinical advances of this treatment technique have been demonstrated by different investigators [23]. ...

... In extranodal RDD forms, prognosis also correlated with the number of organ systems that were involved. Prognosis is usually favorable for cutaneous, nodal, and bone RDD; however, CNS involvement with RDD has variable outcomes [13,16,71]. In most cases, it has a good prognosis; however, some patients have a progressive and fatal course. ...

... A large meta-analysis demonstrated that serum calcium is regulated by the CASR gene and is influenced by its genetic variation [45]. However, the results linking serum calcium levels with PCa progression are mixed with one study showing no association [46] and two other studies reporting a positive association with PCa mortality [47,48]. Three studies have assessed whether common genetic variation of the CASR gene is associated with PCa risk. ...

... A study comparing 3D conformal IMRT and photon therapy and 3D conformal proton beam therapy showed an adequate CTV coverage for all three techniques, but with proton therapy lower doses were delivered to normal tissue, i.e. bowel and kidneys. Also, the total integral radiation dose to the body was lower with protons compared with IMRT and 3D conformal photon therapy [26]. With these lower radiation doses on normal tissue, less late toxicity should be expected using proton beam therapy [25]. ...

... La evidencia actual respecto a radioterapia para sarcomas retroperitoneales es insuficiente, controvertida y sugiere ventajas en control local y supervivencia libre de progresión (especialmente en enfermedad residual), sin embargo, es considerable la radio-toxicidad a órganos y estructuras vitales del retroperitoneo. El control local de TMVNPs se ha asociado a dosis mayores de 60 Gy (3,9,10) . ...